Acute Major Eye Infections without CC/MCC: Inpatient Reimbursement Overview

DRG 122 encompasses inpatient treatment for acute major eye infections without Major Complication or Comorbidity or Complication or Comorbidity, reflecting a specific clinical population with significant resource needs. Correct classification matters for inpatient reimbursement because Medicare payment is prospectively determined by the Diagnosis-Related Group assignment tied to documented diagnoses and procedures.

Customize your policy alerts

Sign up for drg 122 policy alerts

Get alerted when payer policies referencing 122 are released or updated.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

DRG 122 Overview

DRG 122 covers hospital admissions for acute major eye infections that do not have a Major Complication or Comorbidity and do not have a Complication or Comorbidity. These cases typically include severe intraocular or periocular infections requiring inpatient medical or surgical management. This Diagnosis-Related Group is important for Medicare payment because it groups clinically similar resource use to determine a single prospective reimbursement amount. Hospitals and coders must accurately capture principal and secondary diagnoses to ensure correct assignment to this DRG.

Clinical Trials

Early acute intervention trials focusing on topical and local antimicrobial strategies for severe bacterial or fungal keratitis and endophthalmitis: these studies enroll hospitalized adults presenting with vision-threatening acute eye infections to evaluate timing, dosing regimens, and delivery methods (e.g., fortified topical antibiotic drops, intravitreal injections, or local antimicrobial delivery systems). The objective is to determine whether specific early intervention protocols reduce need for surgical procedures, shorten hospital length of stay, and preserve visual acuity; results are directly relevant to inpatient care pathways, resource use, and short-term reimbursement for intensive treatments.
Comparative effectiveness research comparing medical versus surgical management pathways for complicated acute eye infections: trials or observational comparative studies examine subpopulations such as immunocompromised patients, diabetics, or those with prior ocular surgery to compare outcomes of aggressive medical therapy alone versus combined procedures (e.g., debridement, vitrectomy), measuring clinical outcomes, complication rates, and downstream resource utilization. This research informs clinical decision-making about when operative intervention is warranted, impacts coding and DRG assignment decisions, and helps payers and hospitals predict costs and potential readmissions.
Post-discharge outcomes and care coordination studies assessing functional recovery, vision-related quality of life, and readmission risk after inpatient treatment for major eye infections: prospective cohorts or pragmatic trials test different discharge strategies, such as structured outpatient follow-up, home infusion services, or teleophthalmology check-ins, in patients discharged after acute infection treatment. These studies focus on preventing relapse, reducing emergency returns, and optimizing outpatient antimicrobial adherence—issues that affect long-term outcomes, ambulatory care costs, and bundled payment models relevant to payers and providers managing DRG 122 patients.

Related Codes

113-ORBITAL-PROCEDURES-WITH-CC-MCC

Orbital Procedures with CC/MCC: Inpatient Reimbursement Overview

114-ORBITAL-PROCEDURES-WITHOUT-CC-MCC

Orbital Procedures without CC/MCC: Inpatient Reimbursement Overview

115-EXTRAOCULAR-PROCEDURES-EXCEPT-ORBIT

Extraocular Procedures Except Orbit: Inpatient Reimbursement Overview

116-INTRAOCULAR-PROCEDURES-WITH-CC-MCC

Intraocular Procedures with CC/MCC: Inpatient Reimbursement Overview

117-INTRAOCULAR-PROCEDURES-WITHOUT-CC-MCC

Intraocular Procedures without CC/MCC: Inpatient Reimbursement Overview

121-ACUTE-MAJOR-EYE-INFECTIONS-WITH-CC-MCC

Acute Major Eye Infections with CC/MCC: Inpatient Reimbursement Overview

123-NEUROLOGICAL-EYE-DISORDERS

Neurological Eye Disorders: Inpatient Reimbursement Overview

124-OTHER-DISORDERS-OF-THE-EYE-WITH-MCC-OR-THROMBOLYTIC-AGENT

Other Disorders of the Eye with MCC or Thrombolytic Agent: Inpatient Reimbursement Overview

125-OTHER-DISORDERS-OF-THE-EYE-WITHOUT-MCC

Other Disorders of the Eye without MCC: Inpatient Reimbursement Overview

References

1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.

Published by

Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Explore openpayer tools

View all tools

Clinical Trials

Early acute intervention trials focusing on topical and local antimicrobial strategies for severe bacterial or fungal keratitis and endophthalmitis: these studies enroll hospitalized adults presenting with vision-threatening acute eye infections to evaluate timing, dosing regimens, and delivery methods (e.g., fortified topical antibiotic drops, intravitreal injections, or local antimicrobial delivery systems). The objective is to determine whether specific early intervention protocols reduce need for surgical procedures, shorten hospital length of stay, and preserve visual acuity; results are directly relevant to inpatient care pathways, resource use, and short-term reimbursement for intensive treatments.
Comparative effectiveness research comparing medical versus surgical management pathways for complicated acute eye infections: trials or observational comparative studies examine subpopulations such as immunocompromised patients, diabetics, or those with prior ocular surgery to compare outcomes of aggressive medical therapy alone versus combined procedures (e.g., debridement, vitrectomy), measuring clinical outcomes, complication rates, and downstream resource utilization. This research informs clinical decision-making about when operative intervention is warranted, impacts coding and DRG assignment decisions, and helps payers and hospitals predict costs and potential readmissions.
Post-discharge outcomes and care coordination studies assessing functional recovery, vision-related quality of life, and readmission risk after inpatient treatment for major eye infections: prospective cohorts or pragmatic trials test different discharge strategies, such as structured outpatient follow-up, home infusion services, or teleophthalmology check-ins, in patients discharged after acute infection treatment. These studies focus on preventing relapse, reducing emergency returns, and optimizing outpatient antimicrobial adherence—issues that affect long-term outcomes, ambulatory care costs, and bundled payment models relevant to payers and providers managing DRG 122 patients.

Related Codes

113-ORBITAL-PROCEDURES-WITH-CC-MCC

Orbital Procedures with CC/MCC: Inpatient Reimbursement Overview

114-ORBITAL-PROCEDURES-WITHOUT-CC-MCC

Orbital Procedures without CC/MCC: Inpatient Reimbursement Overview

115-EXTRAOCULAR-PROCEDURES-EXCEPT-ORBIT

Extraocular Procedures Except Orbit: Inpatient Reimbursement Overview

116-INTRAOCULAR-PROCEDURES-WITH-CC-MCC

Intraocular Procedures with CC/MCC: Inpatient Reimbursement Overview

117-INTRAOCULAR-PROCEDURES-WITHOUT-CC-MCC

Intraocular Procedures without CC/MCC: Inpatient Reimbursement Overview

121-ACUTE-MAJOR-EYE-INFECTIONS-WITH-CC-MCC

Acute Major Eye Infections with CC/MCC: Inpatient Reimbursement Overview

123-NEUROLOGICAL-EYE-DISORDERS

Neurological Eye Disorders: Inpatient Reimbursement Overview

124-OTHER-DISORDERS-OF-THE-EYE-WITH-MCC-OR-THROMBOLYTIC-AGENT

Other Disorders of the Eye with MCC or Thrombolytic Agent: Inpatient Reimbursement Overview

125-OTHER-DISORDERS-OF-THE-EYE-WITHOUT-MCC

Other Disorders of the Eye without MCC: Inpatient Reimbursement Overview

References

1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.

Published by

Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.